# An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

Study · id `cardio:ct-nct07923526` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07923526](<https://clinicaltrials.gov/study/NCT07923526>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07923526

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07923526. Allocation not applicable; no masking; primary purpose treatment. Start 2027-03 (anticipated); primary completion 2034-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07923526, source copy `cardio:ctgov-nct07923526-2026-11-06`, retrieved 2026-11-18)
- Planned start: 2027-03 (anticipated) (ClinicalTrials.gov record NCT07923526, source copy `cardio:ctgov-nct07923526-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2034-09 (anticipated) (ClinicalTrials.gov record NCT07923526, source copy `cardio:ctgov-nct07923526-2026-11-06`, retrieved 2026-11-18)
- Completion: 2034-09 (anticipated) (ClinicalTrials.gov record NCT07923526, source copy `cardio:ctgov-nct07923526-2026-11-06`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07923526, source copy `cardio:ctgov-nct07923526-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07923526-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
- Acronym: SUMMIT OLE
- Condition: Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
- Intervention (Combination product): treprostinil SMI (treprostinil inhalation spray)
- Lead sponsor: United Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: United Therapeutics (`cardio:org-united-therapeutics`)

## Provenance

Content hash: bcbec09bd9271e50a30d1449f347b330fca385c582e2958dfd6bf3ec3efa7755
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
